Biden’s march-in rights reversal is further evidence of US policy shift on pharma IP rights
US president abandons Trump-era proposal to rule out patent suspensions under the Bayh-Dole Act
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now